FRANKFURT (dpa-AFX) - Too many uncertainties continue to weigh on Evotec shares on Wednesday. In pre-market trading on Tradegate, the shares of the drug researcher slipped by 6.4 percent compared to the Xetra close to 8.93 euros after the presentation of quarterly figures. At the end of April, they had fallen to their lowest level since 2017 at EUR 8.52 and had barely recovered since then.

Evotec recorded a weaker start to the year, but confirmed its forecast for the full year. However, this is to be evaluated together with the new CEO. Evotec appointed Christian Wojczewski as its new CEO on July 1.

One trader said that there are still too many question marks at Evotec. Sales in the first quarter were better than expected, but the adjusted operating result (Ebltda) was significantly worse./ajx/jha/